

LILRB2 antibody - C-terminal region
Rabbit Polyclonal Antibody
Catalog # AI15036**Specification**

LILRB2 antibody - C-terminal region - Product Information

Application	WB
Primary Accession	Q8N423
Other Accession	NM_005874 , NP_005865
Reactivity	Human
Predicted	Human
Host	Rabbit
Clonality	Polyclonal
Calculated MW	65kDa KDa

LILRB2 antibody - C-terminal region - Additional Information**Gene ID** 10288**Alias Symbol** **CD85D, ILT4, LILRA6, LIR-2, LIR2, MIR-10, MIR10****Other Names**

Leukocyte immunoglobulin-like receptor subfamily B member 2, LIR-2, Leukocyte immunoglobulin-like receptor 2, CD85 antigen-like family member D, Immunoglobulin-like transcript 4, ILT-4, Monocyte/macrophage immunoglobulin-like receptor 10, MIR-10, CD85d, LILRB2, ILT4, LIR2, MIR10

Format

Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.

Reconstitution & Storage

Add 50 ul of distilled water. Final anti-LILRB2 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.

Precautions

LILRB2 antibody - C-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.

LILRB2 antibody - C-terminal region - Protein Information**Name** LILRB2 ([HGNC:6606](#))**Function**

Receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C, HLA-G and HLA-F alleles (PubMed: [11169396](http://www.uniprot.org/citations/11169396), PubMed: [12853576](http://www.uniprot.org/citations/12853576), PubMed: [16455647](http://www.uniprot.org/citations/16455647), PubMed: [20448110](http://www.uniprot.org/citations/20448110))

target="_blank">20448110, PubMed:27859042). Involved in the down-regulation of the immune response and the development of tolerance. Recognizes HLA-G in complex with B2M/beta-2 microglobulin and a nonamer self-peptide (peptide-bound HLA-G-B2M) triggering differentiation of type 1 regulatory T cells and myeloid-derived suppressor cells, both of which actively maintain maternal-fetal tolerance (PubMed:16455647, PubMed:20448110, PubMed:27859042). Competes with CD8A for binding to class I MHC antigens. Inhibits FCGR1A-mediated phosphorylation of cellular proteins and mobilization of intracellular calcium ions (PubMed:11875462, PubMed:12853576, PubMed:9548455, PubMed:9842885).

Cellular Location

Cell membrane; Single-pass type I membrane protein

Tissue Location


Expressed in monocytes and at lower levels in myeloid and plasmacytoid dendritic cells. Expressed in tolerogenic IL10-producing dendritic cells (PubMed:20448110). Expressed in myeloid- derived suppressor cells during pregnancy (PubMed:27859042). Detected at low levels in natural killer (NK) cells. Expressed in B cells

LILRB2 antibody - C-terminal region - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

LILRB2 antibody - C-terminal region - Images



WB Suggested Anti-LILRB2 Antibody Titration: 1.0 µg/ml
Positive Control: Fetal Brain

LILRB2 antibody - C-terminal region - References

Colonna M.,et al.J. Exp. Med. 186:1809-1818(1997).
Borges L.,et al.J. Immunol. 159:5192-5196(1997).
Canavez F.C.,et al.Submitted (JUL-2000) to the EMBL/GenBank/DDBJ databases.
Grimwood J.,et al.Nature 428:529-535(2004).
Fanger N.A.,et al.Eur. J. Immunol. 28:3423-3434(1998).